Structural effects of quinacrine binding in the open channel of the acetylcholine receptor.
Noncompetitive inhibitors of the nicotinic acetylcholine (ACh) receptors suppress cation flux directly by binding in and blocking the open channel or indirectly by stabilizing closed states of the receptor. The lidocaine derivative QX-314 and the acridine derivative quinacrine act directly as open channel blockers, but can act indirectly as well. The binding site for quinacrine in the open channel of mouse-muscle ACh receptor was mapped in cysteine-substituted mutants of the alpha subunit expressed with wild-type beta, gamma, and delta subunits. In the open state, substituted cysteines in the inner half of the second membrane-spanning segment (M2), but not in the outer half, were protected by quinacrine from reaction with 2-aminoethyl methanethiosulfonate. In addition, an alkylating derivative, quinacrine mustard, affinity labeled a subset of the substituted cysteines in M2, but only in the open state. These results, mapped onto a model of the open channel surrounded by five alpha-helical M2s, imply that quinacrine binds midway down M2 in the same site previously mapped for QX-314. A cysteine substituted for a residue in the outer third of alphaM1, which reacted with 2-aminoethyl methanethiosulfonate only in the presence of ACh, reacted faster in the additional presence of quinacrine or QX-314. It is proposed that channel opening involves both the opening of the resting gate at the inner end of M2 and the removal of an obstruction formed by the outer end of M1 that retards diffusion of blockers into the closed channel. Blocker binding in the open channel causes a further change in structure.
Yu
Yong
Y
Center for Molecular Recognition, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Shi
Lei
L
Karlin
Arthur
A
D019943:Amino Acid Substitution; D000818:Animals; D001665:Binding Sites; D003545:Cysteine; D005260:Female; D007700:Kinetics; D051379:Mice; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009865:Oocytes / Q000187:drug effects / Q000502:physiology; D017433:Protein Structure, Secondary; D021122:Protein Subunits / Q000737:chemistry / Q000378:metabolism; D011796:Quinacrine / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D011797:Quinacrine Mustard / Q000493:pharmacokinetics / Q000494:pharmacology; D011950:Receptors, Cholinergic / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D014982:Xenopus laevis
D021122:Protein Subunits; D011950:Receptors, Cholinergic; D011994:Recombinant Proteins; D011797:Quinacrine Mustard; D011796:Quinacrine; D003545:Cysteine